Trial Profile
A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2013
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 07 Jul 2011 Results presented at the 14th World Conference on Lung Cancer.
- 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Dec 2010 Primary endpoint 'Progression-free-survival-duration' has been met.